Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 13:9:652970.
doi: 10.3389/fbioe.2021.652970. eCollection 2021.

Mesenchymal Stromal Cells and Their Secretome: New Therapeutic Perspectives for Skeletal Muscle Regeneration

Affiliations
Review

Mesenchymal Stromal Cells and Their Secretome: New Therapeutic Perspectives for Skeletal Muscle Regeneration

Martina Sandonà et al. Front Bioeng Biotechnol. .

Abstract

Mesenchymal stromal cells (MSCs) are multipotent cells found in different tissues: bone marrow, peripheral blood, adipose tissues, skeletal muscle, perinatal tissues, and dental pulp. MSCs are able to self-renew and to differentiate into multiple lineages, and they have been extensively used for cell therapy mostly owing to their anti-fibrotic and immunoregulatory properties that have been suggested to be at the basis for their regenerative capability. MSCs exert their effects by releasing a variety of biologically active molecules such as growth factors, chemokines, and cytokines, either as soluble proteins or enclosed in extracellular vesicles (EVs). Analyses of MSC-derived secretome and in particular studies on EVs are attracting great attention from a medical point of view due to their ability to mimic all the therapeutic effects produced by the MSCs (i.e., endogenous tissue repair and regulation of the immune system). MSC-EVs could be advantageous compared with the parental cells because of their specific cargo containing mRNAs, miRNAs, and proteins that can be biologically transferred to recipient cells. MSC-EV storage, transfer, and production are easier; and their administration is also safer than MSC therapy. The skeletal muscle is a very adaptive tissue, but its regenerative potential is altered during acute and chronic conditions. Recent works demonstrate that both MSCs and their secretome are able to help myofiber regeneration enhancing myogenesis and, interestingly, can be manipulated as a novel strategy for therapeutic interventions in muscular diseases like muscular dystrophies or atrophy. In particular, MSC-EVs represent promising candidates for cell free-based muscle regeneration. In this review, we aim to give a complete picture of the therapeutic properties and advantages of MSCs and their products (MSC-derived EVs and secreted factors) relevant for skeletal muscle regeneration in main muscular diseases.

Keywords: atrophy; extracellular vesicles; mesenchymal stromal cells; muscle; muscle regeneration; muscular dystrophy; secretome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Therapeutic properties of mesenchymal stromal cells (MSCs) and their secretome [soluble factors and extracellular vesicles (EVs)] in various muscle injury models. MSCs derived from different tissues participate in skeletal muscle tissue regeneration, directly or through their secretome (soluble factors and EVs). The cartoon reports the bioactive fraction of the MSC secretome (cytokines, miRs, and growth factors) and the main regenerative processes induced by these factors, as discussed in the main text (↑, upregulation/induction; ↓, downregulation/inhibition). The schematic art pieces used in this figure were provided by Servier Medical art (https://smart.servier.com). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License.

Similar articles

Cited by

References

    1. Allahverdi A., Arefian E., Soleimani M., Ai J., Nahanmoghaddam N., Yousefi-Ahmadipour A., et al. (2020). MicroRNA-4731-5p delivered by AD-mesenchymal stem cells induces cell cycle arrest and apoptosis in glioblastoma. J. Cell. Physiol. 235 8167–8175. 10.1002/jcp.29472 - DOI - PubMed
    1. Andaloussi E. L. S., Mäger I., Breakefield X. O., Wood M. J. A. (2013). Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12 347–357. 10.1038/nrd3978 - DOI - PubMed
    1. Andrade B. M., Baldanza M. R., Ribeiro K. C., Porto A., Peçanha R., Fortes F. S. A., et al. (2015). Bone marrow mesenchymal cells improve muscle function in a skeletal muscle re-injury model. PLoS One 10:e127561. 10.1371/journal.pone.0127561 - DOI - PMC - PubMed
    1. Asari S., Itakura S., Ferreri K., Liu C.-P., Kuroda Y., Kandeel F., et al. (2009). Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol. 37 604–615. 10.1016/j.exphem.2009.01.005 - DOI - PMC - PubMed
    1. Asgarpour K., Shojaei Z., Amiri F., Ai J., Mahjoubin-Tehran M., Ghasemi F., et al. (2020). Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages. Cell Commun. Signal. 18:149. 10.1186/s12964-020-00650-6 - DOI - PMC - PubMed

LinkOut - more resources